Mouse model experiments using human ovarian and lung cancer cells indicate this antibody is effective at reducing proliferation both in vitro and in vivo. Furthermore, the Max Plank Society has written a patent (WO 2010139742A1) to develop an anti-OSMRβ therapeutic for the treatment and/or prevention of heart failure (259). The gene discussed is OSMR; the disease is lung cancer.